In the evolving world of pharmaceutical compounding, regulatory compliance has shifted from a box to check to a line in the sand. As USP <797> and <800> standards become more rigorously enforced, the organizations thriving today aren’t just meeting these requirements—they’re designing their operational strategies around them.
Yet with this shift comes a complex reality: building compliant infrastructure isn’t easy, fast, or always feasible within the constraints of capital budgets, site limitations, or production timelines. That’s why a growing number of industry leaders are embracing a new approach—treating cleanroom compliance as a flexible, scalable capability rather than a fixed asset. Read More >
